Initial Statement of Beneficial Ownership (3)
January 27 2022 - 2:05PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Chen-Walden Hana |
2. Date of Event Requiring Statement (MM/DD/YYYY)
7/15/2021
|
3. Issuer Name and Ticker or Trading Symbol
BIOXYTRAN, INC [BIXT]
|
(Last)
(First)
(Middle)
7 RUE ARISTIDE MAILLOL |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
PARIS, I0 75015
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common | 247800 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Option Plan 2010 | 7/1/2019 | 6/30/2022 | Common | 3000 | $1.09 | D | |
Option Plan 2010 | 10/1/2019 | 9/30/2022 | Common | 3000 | $0.73 | D | |
Option Plan 2010 | 1/1/2020 | 12/31/2023 | Common | 3000 | $0.31 | D | |
Option Plan 2010 | 4/1/2020 | 3/31/2023 | Common | 3000 | $0.32 | D | |
Option Plan 2010 | 7/1/2020 | 6/30/2023 | Common | 3000 | $0.20 | D | |
Option Plan 2010 | 10/1/2020 | 9/30/2023 | Common | 3000 | $0.05 | D | |
Explanation of Responses: |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Chen-Walden Hana 7 RUE ARISTIDE MAILLOL PARIS, I0 75015 | X |
|
|
|
Signatures
|
/s/ Hana Chen-Walden | | 1/18/2022 |
**Signature of Reporting Person | Date |
Bioxytran (QB) (USOTC:BIXT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Bioxytran (QB) (USOTC:BIXT)
Historical Stock Chart
From Aug 2023 to Aug 2024